Latest news with #APIs
Business Standard
a day ago
- Business
- Business Standard
Sai Life Sciences rises on completion of second phase expansion at Bidar facility
Sai Life Sciences rose 1.82% to Rs 742.45 after the company announced the successful commencement of commercial operations for the second phase of the production block at its Unit IV facility in Bidar, Karnataka. The new phase, which became operational on 19 June 2025, adds approximately 91 kL of production capacity. This marks the second and final phase of the total planned capacity addition of approximately 195 kL at the facility, as disclosed in the companys prospectus. With this addition, the total installed capacity at Unit IV now stands at approximately 640 kL. The expanded facility is equipped to manufacture Registered Starting Materials (RSM), intermediates, and Active Pharmaceutical Ingredients (APIs) for both clinical and commercial applications. Hyderabad-based Sai Life Sciences is a leading global contract research, development, and manufacturing organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. The company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. The company's net profit surged 105% to Rs 170 crore on a 16% increase in revenue from operations to Rs 1,695 crore in Q4 March 2025 over Q4 March 2024.
Business Upturn
a day ago
- Business
- Business Upturn
Sai Life Sciences begins commercial operations of expanded Unit IV facility in Bidar
Sai Life Sciences has recently informed exchanges that the company successfully commenced commercial operations of the second phase of its production block at the Unit IV facility in Bidar, Karnataka, as of June 19, 2025. This phase adds around 91 kL of manufacturing capacity, marking the completion of the company's planned 195 kL expansion project at the site, as outlined in its prospectus. With this addition, the total installed capacity at the Bidar facility now stands at approximately 640 kL. The expanded unit is fully equipped to manufacture Registered Starting Materials (RSMs), intermediates, and Active Pharmaceutical Ingredients (APIs), catering to both clinical development and commercial-scale supply. This strategic milestone strengthens Sai Life Sciences' manufacturing footprint and aligns with its long-term growth plans in the pharmaceutical sector. The company's enhanced infrastructure will support its global clientele with high-quality and scalable production capabilities. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
13-06-2025
- Yahoo
Google to End Android Instant Apps by December 2025 Due to Low Usage
Google is set to discontinue Android Instant Apps by the end of 2025. They were first introduced in 2016 and made available to users in early 2017. Android Instant Apps let users try out parts of an app without fully installing it. The service worked by running a lightweight version of an app when a user tapped a link. The Play Store checked if an instant app was available and then launched it temporarily. The thing is, Android Instant Apps struggled to gain traction among developers, and I am assuming even among the users. I personally can't remember using one, ever. To take part, developers had to create a special instant-enabled version of their app that was under 15MB, which proved difficult for apps with large files or complex features, as reported by Android Authority. And now, with much faster internet and higher storage, the already not-so-famous format is of no use. Confirmation of the shutdown comes from a notice in the latest Android Studio canary build: Instant Apps support will be removed by Google Play in December 2025. Publishing and all Google Play Instant APIs will no longer work. Tooling support will be removed in Android Studio Otter Feature Drop. Google says that low usage and engagement are the main reasons for ending Instant Apps.
Mint
13-06-2025
- Business
- Mint
From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees another 53% upside
Multibagger stock Wanbury has emerged as one of the most astonishing success stories on Dalal Street, transforming itself from an obscure penny stock into a headline-maker in five years. From trading at just ₹ 19 in June 2020, the stock has surged more than 1,475 percent to hover around ₹ 299.35 in recent sessions. This translates to a remarkable ₹ 1 lakh investment growing to over ₹ 15.75 lakh. Over the past year alone, Wanbury has rallied nearly 93 percent, delivering impressive returns to investors in a staggered but consistent manner. The multibagger stock has climbed 4 percent in June so far, following a 25.5 percent gain in May, a 1 percent rise in April, and an eye-catching 37 percent surge in March. Despite facing setbacks earlier this year—dropping 25 percent in January and 21 percent in February—Wanbury has bounced back strongly, showcasing persistent buying interest. The stock hit its 52-week high of ₹ 330 last month and its 52-week low of ₹ 151.10 in July 2024. From its Covid-era lows of ₹ 18 per share, the stock has multiplied nearly 1,565 percent — cementing its multibagger credentials. Domestic brokerage Ventura Securities has initiated coverage on Wanbury Ltd with a bullish 'buy' rating, setting a price target of ₹ 458 over the next 24 months. With the stock currently around ₹ 299.35, this target implies a potential upside of 53 percent. Ventura sees robust earnings potential, backed by strong growth in both its API and branded formulations segments. According to the brokerage, Wanbury's revenue is projected to grow at a CAGR of 20 percent from FY25 to FY28, reaching ₹ 1,046 crore. EBITDA and net profit are expected to post even sharper growth at 33 percent and 51 percent CAGR, respectively. By FY28, the company's EBITDA is expected to touch ₹ 177 crore, with net profit at ₹ 104 crore. Margins, too, are set to expand — EBITDA margin is seen improving by 310 basis points to 15.5 percent, while net margin may increase by 290 basis points to 10 percent. As per the brokerage, Wanbury's strength lies in its leadership in Active Pharmaceutical Ingredients (APIs), with a global market share of 10 percent in Metformin and 30 percent in Sertraline. The API division, which largely caters to export markets, is expected to grow at a 16 percent CAGR, reaching ₹ 819 crore by FY28. Its domestic branded formulations business is growing at an even faster clip. Focused on high-margin chronic therapies, this segment is projected to expand at a 47 percent CAGR to ₹ 227 crore by FY28, driven by new product launches and broader customer outreach, it further stated. The company is also recovering from past setbacks, particularly its troubled Spanish formulations venture. A return to profitability in FY24 and positive net worth indicate a successful turnaround. Ventura attributes Wanbury's revival to operational efficiencies and strategic debt refinancing. Looking ahead, Ventura pointed out that the company has allocated ₹ 165 crore for a brownfield expansion at its Tanuku plant, expected to be implemented between FY26 and FY28. This aligns with its strategy of maintaining an asset-light model while scaling up production capabilities.
Business Standard
13-06-2025
- Business
- Business Standard
Sigachi Industries rises after securing ToR nod from SEIAA Andhra Pradesh
Sigachi Industries added 1.15% to Rs 58.10 after the firm informed that it has secured the Terms of Reference (ToR) approval from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh. This key approval is for its upcoming manufacturing facility dedicated to Bulk Drugs, Drug Intermediates, and Specialty Chemicals, including Active Pharmaceutical Ingredients (APIs), to be established at Orvakal in Kurnool District, Andhra Pradesh. This strategic project is proposed over 25.09 acres at Plot No. A-10, Guttapadu-Orvakal Node. The facility falls under Category B1, aligned with Schedule 5(f) of the EIA Notification, 2006, applicable to the Synthetic Organic Chemicals sector. The Environmental Clearance (EC) process for the upcoming facility is set to begin on 15 July 2025, with project development activities scheduled to commence from 1 August 2025. The project is expected to be instrumental in enhancing the companys API manufacturing capacity and strengthening its global presence. It will support the expansion of the product pipeline across regulated and semi-regulated markets, while also establishing a strategically located facility with strong export potential. Additionally, the project aligns with the Make in India initiative, promoting world-class infrastructure and sustainable manufacturing practices. Commenting on this development, Amit Raj Sinha, managing director and CEO of Sigachi Industries stated - This is a significant milestone in our journey to become a vertically integrated pharmaceutical manufacturing company. The Orvakal project will anchor our next phase of growth in APIs and specialty chemicals, helping us create scalable, sustainable, and compliant operations for global markets. At Sigachi, we are strategically positioning ourselves to cater to increasing global demand by building capacity closer to key markets and regulatory jurisdictions. The new facility will not only strengthen our product supply chain but also enable faster commercialization, seamless tech transfers, and enhanced responsiveness to evolving customer requirements. Telangana-based Sigachi Industries is engaged in the manufacturing of microcrystalline cellulose (MCC), which is widely used in the pharmaceutical, food, beverage, cosmetic, and paint industries. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp, which is imported by the company. The companys consolidated net profit tanked 11.8% to Rs 13.27 crore despite 23.1% rise in revenue from operations to Rs 128.20 crore in Q4 FY25 over Q4 FY24.
